- LOTTE Biologics was named “Best New or Relaunched CDMO” at the 2026 CDMO Leadership Awards.
- The recognition is based on industry evaluations across capabilities, quality, reliability, and service.
LOTTE Biologics has been named a recipient in the “Best New or Relaunched CDMO” category at the 2026 CDMO Leadership Awards. The awards are organized by Outsourced Pharma and Life Science Connect and are based on evaluations from industry professionals over the past 24 months.
The CDMO Leadership Awards assess contract development and manufacturing organizations on criteria including capabilities, compatibility, expertise, quality, reliability, and service. The program includes an independent evaluation conducted by the Tufts Center for the Study of Drug Development and is based on nominations from clients or industry peers.
LOTTE Biologics was recognized in a category that highlights companies entering or redefining the CDMO market through strategic direction and operational execution. According to the company, the award reflects its expansion in the global market within four years of launch and customer recognition of its quality and execution capabilities.
The company’s dual-site strategy and experience with more than 62 global regulatory approvals were cited by industry observers as contributing factors. LOTTE Biologics is also expanding its capabilities in antibody-drug conjugates as part of its broader biologics portfolio, alongside ongoing development of its Songdo Bio Campus.
A company representative said, “This award is especially meaningful as it reflects recognition earned within a short period of time in the global CDMO market.” During DCAT Week, the company is also holding private meetings in New York to engage with pharmaceutical and biotechnology partners and explore new contract manufacturing opportunities.
